TABLE 14Measures of global effect in included studies: galantamine vs placebo

StudySubgroupOutcomeTypeArmGalantaminePlacebop-value
NMean, n (%)NMean, n (%)
Brodaty et al. (2005)96LOCF analysisCIBIC-plus score – 26 weeksAo.d.a2914.21 (SD 1.1)3014.35 (SD 1.14)NSb
b.i.d.c3024.21 (SD 1.07)NSb
CIBIC-plus: markedly improved – 26 weeksDo.d.a2913 (1.0)3013 (1.0)0.712d
b.i.d.c3023 (1.0)0.685d
CIBIC-plus: moderately improved – 26 weeksDo.d.a29114 (4.8)30111 (3.7)0.621d
b.i.d.c30215 (5.0)0.553d
CIBIC-plus: minimally improved – 26 weeksDo.d.a29149 (16.8)30148 (15.9)0.856d
b.i.d.c30246 (15.2)0.897d
CIBIC-plus: no change – 26 weeksDo.d.a291114 (39.2)301111 (36.9)0.623d
b.i.d.c302127 (42.1)0.224d
CIBIC-plus: minimally worse – 26 weeksDo.d.a29181 (27.8)30180 (26.6)0.802d
b.i.d.c30278 (25.8)0.907d
CIBIC-plus: moderately worse – 26 weeksDo.d.a29124 (8.2)30141 (13.6)0.050d
b.i.d.c30230 (9.9)0.201d
CIBIC-plus: markedly worse – 26 weeksDo.d.a2916 (2.1)3017 (2.3)0.951d
b.i.d.c3023 (1.0)0.336d
OC populationCIBIC-plus score – 26 weeksAo.d.a2464.19 (SD 1.13)2594.36 (SD 1.15)NSb
b.i.d.c2404.21 (SD 1.11)NSb
CIBIC-plus: markedly improved – 26 weeksDo.d.a2463 (1.2)2593 (1.2)0.728d
b.i.d.c2403 (1.3)0.751d
CIBIC-plus: moderately improved – 26 weeksDo.d.a24614 (5.7)2599 (3.5)0.327d
b.i.d.c24024 (5.8)0.298d
CIBIC-plus: minimally improved – 26 weeksDo.d.a24643 (17.5)25941 (15.8)0.705d
b.i.d.c24036 (15.0)0.895d
CIBIC-plus: no change – 26 weeksDo.d.a24690 (36.6)25994 (36.3)0.981d
b.i.d.c24093 (38.8)0.636d
CIBIC-plus: minimally worse – 26 weeksDo.d.a24669 (28.0)25970 (27.0)0.875d
b.i.d.c24067 (27.9)0.903d
CIBIC-plus: moderately worse – 26 weeksDo.d.a24623 (9.3)25936 (13.9)0.146d
b.i.d.c24025 (10.4)0.294d
CIBIC-plus: markedly worse – 26 weeksDo.d.a2464 (1.6)2596 (2.3)0.812d
b.i.d.c2402 (0.8)0.336d
Rockwood et al. (2006)131LOCF analysisCIBIC-plus score – 8 weeksA613.64 (SD 0.797)654.17 (SD 0.905)
CIBIC-plus score – 16 weeksA613.67 (SD 0.996)654.12 (SD 0.987)0.03e

A, absolute value; b.i.d., twice a day; D, dichotomous; NS, not statistically significant; o.d., once a day.

a

Galantamine prolonged-release formulation once a day.

b

Cochran–Mantel–Haenszel statistic using modified ridit scores, derived from rank score (the van Elteren test) and controlling for country effect (USA vs ex-USA).

c

Galantamine standard formulation twice a day.

d

Chi-squared test (Yates' correction) (calculated by reviewer).

e

Test not stated.

From: 3, Assessment of clinical effectiveness

Cover of The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model
The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model.
Health Technology Assessment, No. 16.21.
Bond M, Rogers G, Peters J, et al.
Southampton (UK): NIHR Journals Library; 2012 Apr.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.